Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$18.17 USD

18.17
21,017,185

-1.39 (-7.08%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $18.17 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for NVAX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Novavax, Inc. [NVAX]

Reports for Purchase

Showing records 181 - 200 ( 296 total )

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 181

01/22/2020

Company Report

Pages: 3

Development of a Coronavirus Vaccine Candidate Initiated; Reiterate Buy and $17 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 182

11/19/2019

Company Report

Pages: 4

We''re Focused on Completion of the NanoFlu Pivotal Trial; Reiterate Buy and $17 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 183

10/15/2019

Daily Note

Pages: 3

Pivotal NanoFlu Phase 3 Initiated; Expect Top-line in 1Q20; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 184

08/14/2019

Company Report

Pages: 5

We Think Novavax Keeps Winning With NanoFlu; Reiterate Buy and Raise PT to $17

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 185

07/01/2019

Company Report

Pages: 5

It''s a Trifecta; Strong, Committed Partner; Intellectual Continuity; NanoFlu Poised for Acceleration; Raising PT to $12

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 186

06/13/2019

Company Report

Pages: 5

ResVax Licensure Pathway Requires Another Phase 3; Reiterate Buy With a Post-Reverse Stock Split Adjusted PT of $10

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 187

05/03/2019

Company Report

Pages: 5

1Q18 Reflects Lower R-D; Update Guides to Regulatory Activities in 2H19; Expecting a 4Q NanoFlu Phase 3; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 188

03/19/2019

Company Report

Pages: 5

4Q18 In-Line; Business Update Shows Discussions Continue With the FDA on ResVax and NanoFlu Next Steps; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 189

03/01/2019

Company Report

Pages: 9

Finding a Silver Lining: Safety, Tolerability and Positive Results Where it Counts; Reiterate Buy but With a $2 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 190

02/28/2019

Daily Note

Pages: 4

It''s hard to adequately prepare for when lightning strikes twice; ResVax Phase 3 trial does not meet primary objective

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 191

01/28/2019

Company Report

Pages: 21

History Could Be Made With ResVax in 2019; Initiate With Buy and $6 PT

Provider: H.C. Wainwright & Co., Inc.

Price: 75.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 192

05/26/2017

Daily Note

Pages: 4

Biotechnology: Dropping Coverage Due to Analyst Departure

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 193

11/10/2016

Company Report

Pages: 6

Novavax Plots Path Forward; Reiterate NEUTRAL and Lowering Price Target to $1.50

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 194

11/04/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov 7

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 195

10/28/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 31

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 196

10/23/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 24

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 197

10/13/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 17

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 198

09/16/2016

Company Report

Pages: 8

The Numbers Don''t Add Up; Downgrading to NEUTRAL with $2 Price Target

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 199

08/19/2016

Industry Report

Pages: 7

The Week Ahead in Life Sciences: Upcoming Events for the Week of August 22

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 200

08/10/2016

Company Report

Pages: 6

Eyes on Pivotal Data as Novavax Reports 2Q16; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party